ClearPoint Neuro (CLPT) director converts 12,417 RSUs into common stock holdings

Rhea-AI Filing Summary

ClearPoint Neuro director Linda M. Liau acquired 12,417 shares of common stock through settlement of restricted stock units. These RSUs were granted on May 22, 2025 and vested on their scheduled date, converting into the same number of common shares. After this compensation-related transaction, she holds 64,801 shares of ClearPoint Neuro common stock directly. No open-market buys or sells were reported in this filing.

Insider Trade Summary

12,417 shares exercised/converted

Mixed 2 txns

Insider LIAU LINDA M.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,417	$0.00	--
Exercise	Common Stock	12,417	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 64,801 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs settled: 12,417 shares Shares acquired: 12,417 shares Post-transaction holdings: 64,801 shares +2 more

5 metrics

RSUs settled 12,417 shares Restricted stock units vesting into common stock

Shares acquired 12,417 shares Common stock received from RSU settlement

Post-transaction holdings 64,801 shares Common stock held directly after transaction

RSU grant date May 22, 2025 Grant date for 12,417 restricted stock units

RSU-to-share ratio 1 RSU : 1 share Each RSU represents one share of CLPT common stock

Key Terms

Restricted Stock Units, derivative security, vested, annual meeting of stockholders

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction code description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vested financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."

annual meeting of stockholders financial

"vesting on the earlier of the first anniversary of the grant date, or the day immediately preceding the Company's 2026 annual meeting of stockholders."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIAU LINDA M.

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		12,417	A	(1)	64,801	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/19/2026		M			12,417	(1)	(1)	Common Stock	12,417	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

	/s/ Danilo D'Alessandro, by Power of Attorney for Linda M. Liau	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CLPT director Linda M. Liau report on this Form 4?

Linda M. Liau reported the settlement of 12,417 restricted stock units into 12,417 shares of ClearPoint Neuro common stock. This reflects scheduled vesting of equity compensation, rather than an open-market stock purchase or sale.

How many ClearPoint Neuro (CLPT) shares did Linda M. Liau acquire in this transaction?

She acquired 12,417 shares of ClearPoint Neuro common stock. These shares came from the vesting and settlement of 12,417 restricted stock units granted as compensation, not from buying shares on the open market.

What are the post-transaction holdings of Linda M. Liau in ClearPoint Neuro (CLPT)?

Following the RSU settlement, Linda M. Liau directly holds 64,801 shares of ClearPoint Neuro common stock. This figure reflects her updated ownership position after the 12,417 vested restricted stock units converted into common shares.

Were the 12,417 ClearPoint Neuro (CLPT) shares bought or sold on the open market?

The 12,417 shares were not traded on the open market. They resulted from the scheduled vesting and settlement of restricted stock units into common stock, a typical equity compensation event for company directors.

What was the original grant date and vesting terms of the CLPT restricted stock units?

The 12,417 restricted stock units were granted on May 22, 2025. They vested on the earlier of the first anniversary of the grant date or the day immediately preceding ClearPoint Neuro’s 2026 annual meeting of stockholders.

Does this CLPT Form 4 indicate any remaining restricted stock units for Linda M. Liau?

This Form 4 shows that 12,417 restricted stock units were fully settled into common shares, leaving zero RSUs from this grant. The derivative summary in the filing does not list any remaining derivative positions for this transaction.